Pyridam Farma Tbk PT
IDX:PYFA

Watchlist Manager
Pyridam Farma Tbk PT Logo
Pyridam Farma Tbk PT
IDX:PYFA
Watchlist
Price: 206 IDR -4.63% Market Closed
Market Cap: 2.3T IDR
Have any thoughts about
Pyridam Farma Tbk PT?
Write Note

Relative Value

The Relative Value of one PYFA stock under the Base Case scenario is 104.39 IDR. Compared to the current market price of 206 IDR, Pyridam Farma Tbk PT is Overvalued by 49%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PYFA Relative Value
Base Case
104.39 IDR
Overvaluation 49%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
19
vs Industry
59
Median 3Y
0.9
Median 5Y
1.3
Industry
2.5
vs History
vs Industry
43
Median 3Y
1.4
Median 5Y
9
Industry
21.8
vs History
26
vs Industry
47
Median 3Y
11.6
Median 5Y
12
Industry
16.1
vs History
80
vs Industry
35
Median 3Y
1.5
Median 5Y
2.1
Industry
23.8
vs History
61
vs Industry
21
Median 3Y
3.1
Median 5Y
3.1
Industry
2.1
vs History
11
vs Industry
37
Median 3Y
1.8
Median 5Y
1.7
Industry
2.7
vs History
3
vs Industry
29
Median 3Y
5.4
Median 5Y
3.9
Industry
5.2
vs History
vs Industry
0
Median 3Y
9.2
Median 5Y
11
Industry
13.5
vs History
vs Industry
0
Median 3Y
9.2
Median 5Y
11
Industry
16.8
vs History
22
vs Industry
38
Median 3Y
23.1
Median 5Y
18.6
Industry
15.2
vs History
12
vs Industry
27
Median 3Y
-4.1
Median 5Y
-3.8
Industry
19.3
vs History
63
vs Industry
45
Median 3Y
1.4
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

PYFA Competitors Multiples
Pyridam Farma Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Pyridam Farma Tbk PT
IDX:PYFA
2.3T IDR 1.7 -9.1 -44 -44
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 18.5 90.3 48.5 54.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 4 23.9 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average P/S: 382 942.1
1.7
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average P/E: 32.4
Negative Multiple: -9.1
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBITDA: 459.6
Negative Multiple: -44
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBIT: 2 011.3
Negative Multiple: -44
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top